MET and neoplasm: Secondly, many studies have confirmed that tumor-associated target antigens commonly expressed in solid tumors are expressed in urologic neoplasms, including MUC1, EGFR, VEGFR2, EpCAM, C-Met, NKG2DL, MUC1, etc. Therefore, the use of CAR-T cells in urologic neoplasms has an advantage over other systemic tumors in the selection of target antigens.